liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
New treatment for IgA nephropathy:  enteric budesonide targeted to the ileocecal region ameliorates proteinuria
Uppsala University.
Karolinska Institutet.
Karolinska Institutet.
Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart and Medicine Centre, Department of Nephrology UHL. Linköping University, Department of Medical and Health Sciences, Nephrology.
Show others and affiliations
2011 (English)In: Nephrology, Dialysis and Transplantation, ISSN 0931-0509, E-ISSN 1460-2385, Vol. 26, no 10, 3237-3241 p.Article in journal (Refereed) Published
Abstract [en]

Background. Systemic corticosteroid treatment has been shown to exert some protection against renal deterioration in IgA nephropathy (IgAN) but is not commonly recommended for long-term use due to the well-known systemic side effects. In this study, we investigated the efficacy and safety of a new enteric formulation of the locally acting glucocorticoid budesonide (Nefecon (R)), designed to release the active compound in the ileocecal region. The primary objective was to evaluate the efficacy of targeted release budesonide on albuminuria. less thanbrgreater than less thanbrgreater thanMethods. Budesonide 8 mg/day was given to 16 patients with IgAN for 6 months, followed by a 3-month follow-up period. The efficacy was measured as change in 24-h urine albumin excretion, serum creatinine and estimated glomerular filtration rate (eGFR). less thanbrgreater than less thanbrgreater thanResults. The median relative reduction in urinary albumin excretion was 23% during the treatment period (interquartile range: -0.36 to -0.04, P = 0.04) with pretreatment values ranging from 0.3 to 6 g/24 h (median: 1.5 g/24 h). The median reduction in urine albumin peaked at 40% (interquartile range: -0.58 to -0.15) 2 months after treatment discontinuation. Serum creatinine was reduced by 6% (interquartile range: -0.12 to -0.02; P = 0.003), and eGFR [Modification of Diet in Renal Disease (MDRD)] increased similar to 8% (interquartile range: 0.02-0.16, P = 0.003) during treatment. No major corticosteroid-related side effects were observed. less thanbrgreater than less thanbrgreater thanConclusions. In the present pilot study, enteric budesonide targeted to the ileocecal region had a significant effect on urine albumin excretion, accompanied by a minor reduction of serum creatinine and a modest increase of eGFR calculated by the MDRD equation, while eGFR calculated from Cockcroft-Gault equation and cystatin C was not changed. Enteric budesonide may represent a new treatment of IgAN warranting further investigation.

Place, publisher, year, edition, pages
Oxford University Press (OUP): Policy B , 2011. Vol. 26, no 10, 3237-3241 p.
Keyword [en]
budesonide, clinical trial, corticosteroid, IgA nephropathy, prospective
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-72664DOI: 10.1093/ndt/gfr052ISI: 000296349200030OAI: diva2:461124
Funding Agencies|Pharmalink AB||Available from: 2011-12-02 Created: 2011-12-02 Last updated: 2012-03-15

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Fernström, AndersPåhlsson, Peter
By organisation
Faculty of Health SciencesDepartment of Nephrology UHLNephrologyCell Biology
In the same journal
Nephrology, Dialysis and Transplantation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 117 hits
ReferencesLink to record
Permanent link

Direct link